Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Markets Stocks ETFs Tools Overview News Currencies International Treasuries Pfizer (NY: PFE ) 49.21 +0.36 (+0.74%) Official Closing Price Updated: 5:00 PM EST, Nov 25, 2022 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 6,772,043 Open 48.93 Bid (Size) 49.15 (2) Ask (Size) 49.29 (7) Prev. Close 48.85 Today's Range 48.84 - 49.22 52wk Range 41.45 - 61.71 Shares Outstanding 5,606,688,356 Dividend Yield 3.17% Intraday 1 Week 1 Month 3 Month 1 Year Top News More News Is Novavax Stock a Buy Now? Today 10:37 EST There's probably not much good news coming for this biotech in the near future. Via The Motley Fool Better Dividend Stock: AbbVie or Viatris? Today 8:15 EST These pharmaceutical companies are profitable and offer above-average dividends. Via The Motley Fool Performance YTD -13.13% -13.13% 1 Month +7.59% +7.59% 3 Month +6.45% +6.45% 6 Month -7.22% -7.22% 1 Year -8.87% -8.87% More News Read More Nutraceutical Supplements Market to Witness Huge Growth : Glanbia, Pfizer, Bayer, DowDuPont November 25, 2022 Via SBWire European Official Says COVID-19 Booster Uptake Disappointing In The Region November 25, 2022 Via Benzinga A Look Into Healthcare Sector Value Stocks November 21, 2022 Via Benzinga 8 Analysts Have This to Say About Pfizer November 18, 2022 Via Benzinga Researchers Working On Universal mRNA-Influenza Vaccine Aiming For Baseline Immune Memory For Diverse Strains November 25, 2022 Via Benzinga Is Now the Time for Income Investors to Buy This Big Pharma Stock? November 24, 2022 Via The Motley Fool Novavax Stock: Buy, Sell, or Hold in 2023? November 24, 2022 Via The Motley Fool Mirati Therapeutics Surges As Big Pharma Reportedly Preps For A Buyout Battle November 23, 2022 Via Investor's Business Daily How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market November 23, 2022 Via Benzinga PFE Stock Could Be the Booster Shot Your Portfolio Needs Now November 23, 2022 Via InvestorPlace Graphic design as a service Company Doozoo secures strategic investment partner, launches fresh branding and expands resource within USA to meet growing global demand. November 22, 2022 Via Get News Jim Cramer Says China's Vaccines 'Don't Work' But Xi Won't Admit It November 22, 2022 Via Benzinga 10 Health Care Stocks Whale Activity In Today's Session November 22, 2022 Via Benzinga Arvinas's ARV-471 Achieves Clinical Benefit Rate Of 38% In Breast Cancer Setting November 22, 2022 Via Benzinga Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC) November 22, 2022 From Arvinas Inc. Via Globe NewsWire 2 Reasons to Buy Pfizer and 1 Reason to Sell November 20, 2022 Via The Motley Fool 3 Unstoppable Growth Stocks to Buy and Hold November 19, 2022 Via The Motley Fool Here's What Value Stocks Can Do for a Growth Investor November 18, 2022 Via The Motley Fool Pfizer Is Worst-Performing US Large-Cap Pharma Stock This Year, Its Investment Case Is Complex Yet Rewarding November 18, 2022 Via Benzinga Pfizer/BioNTech's Omicron Tailored COVID-19 Vaccine Shows Improved Immune Response Against Emerging Omicron Sublineages November 18, 2022 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022 November 18, 2022 Via Benzinga Market Rally Holds Key Levels, But Breakouts Struggle; Walmart, Target, Nvidia In Focus: Weekly Review November 18, 2022 Via Investor's Business Daily Pfizer, BioNTech Take Next Step Toward A Pan-Covid Vaccine — But Is The Demand There? November 17, 2022 Via Investor's Business Daily Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
